BioCentury
ARTICLE | Company News

Helsinn, Chugai sales and marketing update

November 18, 2013 8:00 AM UTC

Helsinn granted Chugai's Chugai Pharma Marketing Ltd. subsidiary commercialization rights to anamorelin ( ONO-7643) in Germany, France, Benelux, the U.K. and Ireland. The product is in Phase III testing to treat anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC). Helsinn will retain all development rights and be responsible for regulatory submissions for the small molecule ghrelin mimetic. Chugai said it expects regulatory applications will be submitted after 2015, but the company declined to disclose details, including financial terms. Helsinn declined to disclose details. ...